Revolution Medicines Advances Daraxonrasib Into Phase 3 Pancreatic Cancer Trial, Extending Long-Term Upside Potential

Revolution Medicines, Inc. (RVMD) announced an update on their ongoing clinical study.

Study Overview

Revolution Medicines, Inc. is running a Phase 3 trial called “RASolute 304” to test its drug daraxonrasib (RMC-6236) in patients with pancreatic ductal adenocarcinoma (PDAC) who have had surgery and chemotherapy. The goal is to see if adding this targeted pill after standard treatment can lower the risk of the cancer coming back, compared with today’s usual approach of simple observation. Because PDAC has few effective options and high relapse rates, any positive data from this study could be important for both patients and investors.

Intervention/Treatment

The study is testing daraxonrasib, an oral drug designed to block a key cancer-driving signal in RAS-mutated tumors. Patients in the active arm will take daraxonrasib tablets, while the control group will receive standard post‑treatment monitoring only, without extra drugs. The goal is to show that a daily targeted pill after surgery and chemotherapy can provide added benefit over watch‑and‑wait care.

Study Design

This is an interventional Phase 3 trial with patients randomly assigned to one of two groups: daraxonrasib or standard observation. The model is “parallel,” meaning both groups are treated and followed at the same time. The study is open‑label with no masking, so both doctors and patients know who is getting the drug. The main purpose is to test whether daraxonrasib improves outcomes as a treatment given after standard therapy.

Study Timeline

The study was first submitted in November 2025, marking the formal start of the clinical and regulatory process. It is currently listed as recruiting, showing that sites are open and enrolling patients. The last update on the trial record was posted on December 23, 2025, signaling that the sponsor is actively maintaining the listing. Primary completion and final completion dates are not yet specified, but investors should assume several years to full data, typical for large post‑surgery cancer trials.

Market Implications

This update confirms that Revolution Medicines is moving its RAS‑targeted pipeline into a large, unmet cancer setting where successful adjuvant drugs can support blockbuster‑level revenue. The launch of a Phase 3 trial in resected PDAC strengthens the company’s late‑stage story and may support sentiment for RVMD as investors look for clear registration paths beyond early‑stage data. Competition in RAS‑driven cancers remains intense, with major players also developing targeted agents, but few have advanced programs focused on post‑surgery pancreatic cancer. If daraxonrasib shows a clear benefit in preventing relapse, it could provide a differentiated position in a difficult market segment and potentially drive future premium valuations. For now, the impact is mostly on expectations: the trial adds long‑term upside optionality but will not affect near‑term revenue, so share price reactions are likely to track broader biotech risk appetite and any interim updates or enrollment milestones.

The daraxonrasib Phase 3 study in resected PDAC is ongoing and recently updated, with further details available on the ClinicalTrials.gov portal under its listed identifier.

To learn more about RVMD’s potential, visit the Revolution Medicines, Inc. drug pipeline page.